Meet the faculty
Program Director
Fernando Lopez-Rios
Director, Molecular Diagnostics Service, Hospital Universitario 12 de Octubre, Madrid, Spain
Fernando Lopez-Rios has recently joined the Department of Pathology at “12 de Octubre” University Hospital (Madrid) as the Chief of the Molecular Diagnostics Service. He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University respectively and completed his residency in Pathology at “12 de Octubre” University Hospital (Madrid). Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at “HM Hospitales” and a visiting researcher at Memorial Sloan Kettering Cancer Center (USA). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is currently a member of the IASLC Pathology Committee.
Disclosures:
Grants/research support: Lilly, Roche, Thermo Fisher Scientific
Honoraria or consultation fees: Lilly, Roche, Thermo Fisher Scientific, Astra Zeneca, Bayer, Takeda, Janssen, MSD, BMS, Pfizer
Alexander Drilon
Chief, Early Drug Development,
Memorial Sloan Kettering Cancer Center, New York, USA
Dr. Alexander Drilon is the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York. His research focuses on the development of targeted therapy for genomic subsets of lung cancer and other solid tumors, including cancers that harbor fusions involving ALK, ROS1, RET, and NTRK1/2/3, and MET exon 14 skipping alterations. He is a recipient of American Society for Clinical Oncology (ASCO)/Conquer Cancer Foundation Career Development and Young Investigator Awards, and grants from the International Association for the Study of Lung Cancer and the Lung Cancer Research Foundation. Dr. Drilon is also a member of the Editorial Board of ASCO University.
Disclosures:
Honoraria/advisory boards: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, I3 Health, MonteRosa, Innocare, Boundless Bio
Equity: Treeline Bio
Associated research paid to institution: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar
Copyright: Selpercatinib-Osimertinib (filed/pending)
Research: Foundation Medicine
Royalties: Wolters Kluwer
Other (food/beverage): Merck, Puma, Merus, Boehringer Ingelheim
CME honoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, Remedica Ltd., Lungevity.
Caterina Marchiò
Associate Professor of Pathology, University of Turin, Italy
Dr. Caterina Marchiò is an Experimental Pathologist leading the Research Program of the Pathology Unit at the Candiolo Cancer Institute.
Dr. Marchiò is devoted to deconvoluting the complexity of Pathology to foster precision medicine. She is also actively involved in the standardization of preanalytical conditions of tissue sample management and processing, to guarantee quality of DNA, RNA and antigens.
She has been involved in the ESMO Translational Research and Precision Medicine Working Group and led the consensus recommendation paper on the standard methods to detect NTRK fusions in daily practice and clinical research.
Disclosures:
Honoraria or consultation fees: Bayer, Roche, Daiichi Sankyo, AstraZeneca
Alex Miles
Police Officer and Patient
Alex has worked in law enforcement in the UK for almost 25 years. He is husband to his beautiful wife and father to four wonderful children. He loves exercise and fitness and his hobbies include watching his beloved Tottenham Hotspur when he can. He was diagnosed with lung cancer in 2019, but continues to fight and enjoy life to the full.
Disclosures:
None to declare
